Xenpozyme is indicated as an enzyme replacement therapy for the treatment of non-Central Nervous System (CNS) manifestations of Acid Sphingomyelinase Deficiency (ASMD) in paediatric and adult patients with type A/B or B.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
